$SPRCAug 24, 2026, 12:51 PMAI processed
NeuroThera/Clearmind US patent application published for MDMA+PEA combo to treat PTSD
AI Summary
NeuroThera (SciSparc subsidiary) and Clearmind published a U.S. patent application covering a combination of MDMA and N-acylethanolamines (e.g., PEA) for treating PTSD, anxiety and eating disorders, expanding their joint IP portfolio and describing potential impacts on MDMA’s potency, dosing, side-effect profile and therapeutic window. The publication coincides with the FDA finalizing guidance that explicitly includes MDMA in psychedelic drug development—providing regulatory context for the IP but the filing is an application (not a granted patent) and the release contains no clinical efficacy or safety data.
Positives
- U.S. patent application published covering MDMA + N-acylethanolamines (e.g., PEA) for PTSD/anxiety/eating disorders
- Adds to NeuroThera–Clearmind joint IP portfolio (now 13 published patent applications globally)
- FDA finalized guidance explicitly includes MDMA, giving clearer regulatory context for psychedelic drug development
Negatives
- Publication is a patent application, not an issued patent
- No clinical trial results or human data reported to support efficacy or safety
- FDA guidance clarifies expectations but does not guarantee approval or a defined regulatory pathway